Vaxcyte's 31-valent PCV candidate VAX-31 receives IND clearance for invasive pneumococcal disease
Oct. 20, 2023
Vaxcyte Inc. has received FDA clearance of its IND application for VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease.